Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

274918-46-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI)

    Cas No: 274918-46-6

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 274918-46-6 Structure
  • Basic information

    1. Product Name: Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI)
    2. Synonyms: Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI)
    3. CAS NO:274918-46-6
    4. Molecular Formula: C10H17NO3
    5. Molecular Weight: 199.24688
    6. EINECS: N/A
    7. Product Categories: N-BOC
    8. Mol File: 274918-46-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 286.6±33.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.002±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 11.30±0.46(Predicted)
    10. CAS DataBase Reference: Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
    11. NIST Chemistry Reference: Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI)(274918-46-6)
    12. EPA Substance Registry System: Carbamic acid, (1-formyl-3-butenyl)-, 1,1-dimethylethyl ester (9CI)(274918-46-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 274918-46-6(Hazardous Substances Data)

274918-46-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 274918-46-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,4,9,1 and 8 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 274918-46:
(8*2)+(7*7)+(6*4)+(5*9)+(4*1)+(3*8)+(2*4)+(1*6)=176
176 % 10 = 6
So 274918-46-6 is a valid CAS Registry Number.

274918-46-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(tert-butoxycarbonyl)allylglycinal

1.2 Other means of identification

Product number -
Other names (1-Formyl-but-3-enyl)-carbamic acid tert-butyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:274918-46-6 SDS

274918-46-6Relevant articles and documents

ALIPHATIC PROLINAMIDE DERIVATIVES

-

, (2018/04/11)

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

Conformationally constrained analogues of bleomycin A5

Rishel, Michael J.,Thomas, Craig J.,Tao, Zhi-Fu,Vialas, Corine,Leitheiser, Christopher J.,Hecht, Sidney M.

, p. 10194 - 10205 (2007/10/03)

The bleomycin (BLM) group antitumor antibiotics are glycopeptide-derived natural products shown to cause sequence selective lesions in DNA. Prior studies have indicated that the linker region, composed of the methylvalerate and threonine residues, may be responsible for a conformational bend in the agent required for efficient DNA cleavage. We have synthesized a number of conformationally constrained methylvalerate analogues and incorporated them into deglycobleomycin A5 congeners using our recently reported procedure for the solid phase construction of (deglyco)bleomycin and its analogues. These analogues were designed to probe the effects of conformational constraint of the native valerate moiety. Initial experiments indicated that the constrained molecules, none of which mimic the conformation proposed for the natural valerate linker, possessed DNA cleavage activity, albeit with potencies less than that of (deglyco)BLM and lacking sequence selectivity. Further experiments demonstrated that these analogues failed to produce alkali-labile lesions in DNA or sequence selective oxidative damage in RNA. However, two of the conformationally constrained deglycoBLM analogues were shown to mediate RNA cleavage in the absence of added Fe2+. The ability of the analogues to mediate the oxygenation of small molecules was also assayed, and it was shown that they were as competent in the transfer of oxygen to low molecular weight substrates as the parent compound.

α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitors

Han, Wei,Hu, Zilun,Jiang, Xiangjun,Decicco, Carl P.

, p. 711 - 713 (2007/10/03)

Peptide-based α-ketoamides, α-ketoesters and α-diketones were designed, synthesized and evaluated against HCV NS3 protease. α-Ketoamides have the highest affinity among the three classes, with 8 being the most potent inhibitor with an IC50 of 3

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 274918-46-6